tbuckley/cabot-search huggingface dataset:
Abstract 18311: Metabolomic Signatures of Right Ventricular-Pulmonary Vascular Dysfunction
Authors: Gregory D Lewis, Laurie Farrell, Carly Domos, Bishnu Dhakal, Xu Shi, Sumita Sinha, Marc J Semigran, Thomas J Wang, Marc S Sabatine, Clary B Clish, Robert E Gerszten
Journal: Circulation (2012)

Impaired performance of the right ventricular-pulmonary vascular (RV-PV) unit is an important determinant of reduced exercise capacity, morbidity and mortality. We sought to determine comprehensive plasma metabolite signatures of RV-PV dysfunction. Methods/Results: We studied subjects who underwent incremental cycle ergometry cardiopulmonary exercise testing with simultaneous hemodynamic monitoring to evaluate the etiology of dyspnea on exertion. In derivation and validation groups (n=71 and n=52, respectively) we performed multi-site blood sampling from the pulmonary and radial arteries to determine plasma concentrations of 130 metabolites using targeted liquid chromatography/mass spectrometry. Indicators of abnormal RV-PV function (i.e. elevated resting right atrial pressure, mean pulmonary arterial pressure [mPAP], pulmonary vascular resistance [PVR], as well as PVR and PAP-flow response [PQ] during exercise) were associated with levels of multiple groups of metabolites ( Table ), including arginine- nitric oxide (NO) pathway intermediates, indicators of oxidative stress, TCA cycle metabolites, and indoleamine 2,3-dioxygenase (IDO)-dependent tryptophan metabolites (TMs). Higher levels of IDO-TMs were the leading predictors of resting mPAP and PVR and exercise PVR and PQ. Transpulmonary release of IDO-TMs localized metabolic changes to the pulmonary circulation. Multivariate regression adjusting for age, gender, BMI, cystatin C, and NT-BNP did not attenuate the relationship between IDO-TMs and indices of RV-PV dysfunction. Conclusion: Metabolic profiling identified signatures of RV-PV dysfunction. These signatures consisted of metabolites known to be associated with RV-PV dysfunction (i.e. NO pathway intermediates, indicators of oxidative stress) and metabolites not previously associated with RV-PV dysfunction (i.e. TCA cycle metabolites and IDO-TMs), which represent potential novel biomarkers of RV-PV dysfunction.
longitudinal exploratory analysis of prior- surgery everolimus circulating and clinical biomarkers in locally advanced and metastatic renal cell carcinoma patients (RCC)
Authors: R. Elaidi, D. Helley, L. Mauge, C. Badoual, E. Tartour, E. Braychenko, L. Albiges, B. Escudier, S. Oudard
Journal: Annals of Oncology (2017)
Prediction of major complications in patients with solid tumors and apparently stable febrile neutropenia: Validation of the CISNE risk score.
Authors: Javier Espinosa, Carme Font, Paula Jiménez-Fonseca, Merce Biosca, Avinash Ramchandani, Maite Antonio Rebollo, Eva Martinez de Castro, Jorge Hernando, Ismael Ghanem, Jeronimo Martinez, Carmen Beato, Ana Blasco, Filipe Casao, Yaiza Bonilla, Rebeca Mondejar, Maria Angeles Arcusa Lanza, Elena Gallardo Martin, Juan Virizuela Echaburu, Francisco Ayala, Alberto Carmona Bayonas
Journal: Journal of Clinical Oncology (2014)

9620 Background: In order to improve the risk stratification of patients with febrile neutropenia (FN), we previously developed a prognostic score predicting major complications in patients with solid tumors and apparently stable episodes (Br J Cancer. 2011;105[5]:612-7). Methods: On the basis of our previous multivariate analysis, 6 predictors were associated to serious complications [ECOG PS≥2 (2points), chronic obstructive pulmonary disease (1point), cardiovascular disease (1point), mucositis NCI grade≥2 (1point), monocytes <200 (1point) and stress-induced hyperglycemia (2points)]. We have integrated these factors into a score ranging from 0 to 8, which allows the classification of patients into 3 prognostic classes: low (0points), medium (1-2points) and high risk (≥ 3points). We present here a validation of this score (CISNE) and a comparison with MASCC and Talcott models. Results: From Oct/12 to Dec/13, we prospectively recruited 780 patients with apparently stable FN from 21 hospitals. The rate of infection-related complications and death was 15.6% (95%CI, 12.9%-18.6%) and 1.7% (95%CI, 0.9%-3%), respectively. CISNE classified 26%, 41% and 33% of the patients as low, medium and high risk, respectively. The rate of complications and death within each of these groups was 1.5%, 7.5% and 37.1% (p<0.001), and 0, 0.9% and 4.3%, respectively (p<0.001). The Table summarizes the comparison of the 3 scales to predict serious complications. The AUCs were 0.84 (95%CI, 0.81-0.86) for CISNE; 0.72 (95%CI, 0.68-0.75) for MASCC and 0.57 (95%CI, 0.54-0.61) for Talcott. Conclusions: CISNE is a valid score that classifies apparently stable FN episodes more accurately than MASCC and Talcott. Parameter CISNE (<3 vs ≥3) MASCC (<21 vs ≥21) Talcott (I-III vs IV) Sensitivity % (CI-95%) 77.8% (69.4- 84.8) 35.2% (26.8 - 44.4) 27.8% (20.1-36.7) Specificity % (CI-95%) 75.5% (72-78.7) 87.6% (84.9-90.1) 87.5% (84.7-89.6) PPV % (CI-95%) 37.1% (31.1-43.3) 34.6% (26.3-43.7) 29.1% (21.2 -38.48) NPV % (CI-95%) 94.8% (92.5-96.5) 87.9% (85.2-90.3) 86.7% (83.9-89.2) pLR (CI-95%) 3.18 (2.7-3.75) 2.86 (2.09-3.92) 2.24 (1.58-3.17) nLR (CI-95%) 0.29 (0.21-0.41) 0.74 (0.65-0.84) 0.82 (0.74-0.92)
Abstract 18139: Genetic Deficiency of Traf-1 Attenuates Diet-Induced Adipose Tissue Inflammation by Limiting the Pool of Circulating and Splenic Monocytes in Mice
Authors: Dennis Wolf, Nathaly Anto Michel, Sonja Hergeth, Peter Stachon, Christoph Bode, Andreas Zirlik
Journal: Circulation (2013)

Background: Accumulation of inflammatory leukocytes, such as of macrophages, is a prerequisite of adipose tissue inflammation during the metabolic syndrome. We recently reported that genetic deficiency of Tumor necrosis factor receptor-associated factor (TRAF) -1 attenuated inflammatory cell recruitment in atherosclerosis. Here, we tested the hypothesis that TRAF-1 deficiency modulates adipose tissue inflammation in a model of diet-induced obesity (DIO) in mice. Methods and Results: To test the association of TRAFs and adipose tissue inflammation we screened for expression of different TRAFs in mouse adipose tissue after 20 weeks of feeding with a high fat (HFD) or a control diet. HFD induced up-regulation of TRAF-1, -3, -5, -6, and -7 mRNA. Interestingly, the amplitude of gene regulation was highest for TRAF-1 (4.9-fold, n=8 per group, p=0.002). Also, in human subcutaneous tissue TRAF-1 gene expression correlated with body mass index of donors (r=0.94, p=0.019). To test functional relevance of our findings, WT or TRAF-1-/- mice consumed HFD for 12 weeks (n ≥ 10 mice per group). Interestingly, TRAF-1-/- mice gained less weight during DIO (119 ± 7.5 % vs. 41 ± 3.7 % of starting body weight for WT and TRAF-1-/-, respectively). Accordingly, total body weight, weight of visceral and cardiac fat pads was decreased in TRAF-1-/- mice. Moreover, TRAF-1-/- mice demonstrated lower glucose levels after starving and during weight-adapted intraperitoneal glucose and insulin tolerance tests, suggesting functional involvement of TRAF-1 in insulin and glucose signaling. Finally, inflammatory cell recruitment was impaired in TRAF-1-/- mice with reduced numbers of adipose tissue macrophages. Functionally, circulating and splenic, but not bone marrow monocytes were lowered in TRAF-1-/- mice, proposing that TRAF-1 modulates monocyte mobilization during inflammation. Conclusion: We present the novel finding that TRAF-1 is regulated in obese murine and human adipose tissue. Genetic deficiency of TRAF-1 attenuates adipose tissue inflammation in mice by limiting monocyte recruitment. These findings identify TRAF-1 as a potent mediator at the interface of cardiovascular and metabolic disease.
Does Use of Bilateral Internal Mammary Artery Grafting Reduce Long-Term Risk of Repeat Coronary Revascularization?
Authors: Alexander Iribarne, Joseph D. Schmoker, David J. Malenka, Bruce J. Leavitt, Jock N. McCullough, Paul W. Weldner, Joseph P. DeSimone, Benjamin M. Westbrook, Reed D. Quinn, John D. Klemperer, Gerald L. Sardella, Robert S. Kramer, Elaine M. Olmstead, Anthony W. DiScipio
Journal: Circulation (2017)

Background: Although previous studies have demonstrated that patients receiving bilateral internal mammary artery (BIMA) conduits during coronary artery bypass grafting have better long-term survival than those receiving a single internal mammary artery (SIMA), data on risk of repeat revascularization are more limited. In this analysis, we compare the timing, frequency, and type of repeat coronary revascularization among patients receiving BIMA and SIMA. Methods: We conducted a multicenter, retrospective analysis of 47 984 consecutive coronary artery bypass grafting surgeries performed from 1992 to 2014 among 7 medical centers reporting to a prospectively maintained clinical registry. Among the study population, 1482 coronary artery bypass grafting surgeries with BIMA were identified, and 1297 patients receiving BIMA were propensity-matched to 1297 patients receiving SIMA. The primary end point was freedom from repeat coronary revascularization. Results: The median duration of follow-up was 13.2 (IQR, 7.4–17.7) years. Patients were well matched by age, body mass index, major comorbidities, and cardiac function. There was a higher freedom from repeat revascularization among patients receiving BIMA than among patients receiving SIMA (hazard ratio [HR], 0.78 [95% CI, 0.65–0.94]; P =0.009). Among the matched cohort, 19.4% (n=252) of patients receiving SIMA underwent repeat revascularization, whereas this frequency was 15.1% (n=196) among patients receiving BIMA ( P =0.004). The majority of repeat revascularization procedures were percutaneous coronary interventions (94.2%), and this did not differ between groups ( P =0.274). Groups also did not differ in the ratio of native versus graft vessel percutaneous coronary intervention ( P =0.899), or regarding percutaneous coronary intervention target vessels; the most common targets in both groups were the right coronary ( P =0.133) and circumflex arteries ( P =0.093). In comparison with SIMA, BIMA grafting was associated with a reduction in all-cause mortality at 12 years of follow-up (HR, 0.79 [95% CI, 0.69–0.91]; P =0.001), and there was no difference in in-hospital morbidity. Conclusions: BIMA grafting was associated with a reduced risk of repeat revascularization and an improvement in long-term survival and should be considered more frequently during coronary artery bypass grafting.
The prognostic significance of infiltrating lymphocytes in resectable pancreatic ductal adenocarcinoma in untreated versus neoadjuvant treated patients
Authors: J.B. Goldstein, D. Chatterjee, M. Zaid, B. Chaudhury, D. Elganainy, D.M. Halperin, R. Nejati, H. Wang, M.H. Katz, J.E. Lee, J. Fleming, J. Rodriguez Canales, J. Blando, I.I. Wistuba, A. Maitra, R.A. Wolff, H. Wang, G.R. Varadhachary, E. Koay
Journal: Annals of Oncology (2017)
Type III interferon is a critical regulator of innate antifungal immunity
Authors: Vanessa Espinosa, Orchi Dutta, Constance McElrath, Peicheng Du, Yun-Juan Chang, Bryan Cicciarelli, Amy Pitler, Ian Whitehead, Joshua J. Obar, Joan E. Durbin, Sergei V. Kotenko, Amariliz Rivera
Journal: Science Immunology (2017)

Type III interferons activate neutrophils to promote antifungal immune responses to Aspergillus fumigatus .
GW28-e1119 Development and Validation of A Scoring System for Predicting Long-Term Ischemic Events in Patients with Coronary Artery Disease
Authors: Miaohan Qiu, Yaling Han, Yi Li, Xiaozeng Wang, Jing Li, Heyang Wang, Xiaofan Yu, Dan Bao, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer
Authors: A.M. Tsimberidou, C. Verschraegen, A. Weise, J. Sarantopoulos, G. Lopes, J. Nemunaitis, A. Victor, J. Shaw, R. Kaleta, R. Kurzrock
Journal: Annals of Oncology (2017)
Effect of Different Iron Preparations for Young Children With Iron-Deficiency Anemia
Authors: Tetsuji Fujita
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018)
Authors: S. Danson, P. Woll, J. Edwards, K. Blyth, P. Fisher, J. Roman, K. Simpson, R. Spavin, K. Learmonth, J. Conner
Journal: Annals of Oncology (2017)
PTEN drives Th17 cell differentiation by preventing IL-2 production
Authors: Hyeong Su Kim, Sung Woong Jang, Wonyong Lee, Kiwan Kim, Hyogon Sohn, Soo Seok Hwang, Gap Ryol Lee
Journal: The Journal of Experimental Medicine (2017)

T helper 17 (Th17) cells are a CD4+ T cell subset that produces IL-17A to mediate inflammation and autoimmunity. IL-2 inhibits Th17 cell differentiation. However, the mechanism by which IL-2 is suppressed during Th17 cell differentiation remains unclear. Here, we show that phosphatase and tensin homologue (PTEN) is a key factor that regulates Th17 cell differentiation by suppressing IL-2 production. Th17-specific Pten deletion (Ptenfl/flIl17acre) impairs Th17 cell differentiation in vitro and ameliorated symptoms of experimental autoimmune encephalomyelitis (EAE), a model of Th17-mediated autoimmune disease. Mechanistically, Pten deficiency up-regulates IL-2 and phosphorylation of STAT5, but reduces STAT3 phosphorylation, thereby inhibiting Th17 cell differentiation. PTEN inhibitors block Th17 cell differentiation in vitro and in the EAE model. Thus, PTEN plays a key role in Th17 cell differentiation by blocking IL-2 expression.
Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)
Authors: J. Tabernero, P.M. Hoff, L. Shen, A. Ohtsu, M.A. Shah, K. Cheng, C. Song, H. Wu, J. Eng-Wong, Y-K. Kang
Journal: Annals of Oncology (2017)
Evaluation of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs)
Authors: A. Prawira, A.B. Stundzia, P. Dufort, J. Halankar, D.M. Paravasthu, A. Spreafico, A.R. Hansen, A.R. Abdul Razak, P.L. Bedard, M. Butler, S. Lheureux, A.M. Oza, R.W. Jang, K.M. Suta, S. Boross-Harmer, J. Cipollone, H. Chow, U. Metser, L.L. Siu
Journal: Annals of Oncology (2017)
An observational study of patients with HER2-positive metastatic gastric cancer treated with trastuzumab: Single center experience.
Authors: Fatma Bugdaycı Basal, Umut Demirci, Ferit Aslan, Ozan Yazici, Berna Oksuzoglu
Journal: Journal of Clinical Oncology (2017)

e15500 Background: In this study, during a 54-month follow-up period, we presented clinicopathological features and survival results of patients treated with trastuzumab. Methods: We retrospectively analyzed the efficacy of trastuzumab-based chemotherapy in 21 patients with HER2-positive gastric cancer between January 2012 and July 2016. Results: Eighteen (86%) patients were male with a median age of 61 (34-80) years. One of the patients was stage 2, 2 were stage 3 and 18 were stage 4, at the time of diagnosis. From 21 tumours, 11 (52%) were located in the cardia, 5 (23%) in the antrum and 5 (23%) in the corpus. In the histopathological examination, 18 (86%) cases were adenocarcinoma and 3 (14%) were signet-ring cell. Seven of the patients with metastatic disease were operated (total/subtotal gastrectomi). The most common metastatic sites were liver (%86), lung(%33), distant lymph node(%23), and periton(%14). Trastuzumab was administered in combination with chemotherapy as first-line treatment and beyond progression as a secondline, and third-line treatment in 18, 2, and 1 patients, respectively. When tumour response was assessed after three cycles of chemotherapy, one complete response (5%),4 partial response (19%),12 stabil disease (57%) were observed, and 4 (19%) patients had progressive disease. Clinical benefit rate was 81%. The maintenance treatment of trastuzumab was applied to 10 patients (47%). At a median follow-up of 17.8 (5-38) months, median progression-free survival was 12.8 months (3-31) and overall survival 18.6 months (3-91). Conclusions: Proximal gastric carcinomas with intestinal phenotype are found to have a higher expression of HER2-gene (range 8-34%) than distal diffuse gastric carcinomas (range 1-7%). The present results are similar to those of the ToGA study in terms of overall survival and response rate.
Prevalence and baseline clinico-pathological associations of germline deleterious mutations in DNA repair genes (gmDDR) in a metastatic castration resistant prostate cancer (mCRPC) prospective spanish cohort (PROREPAIR-B study)
Authors: N. Romero Laorden, R. Lozano Mejorada, J.M. Piulats Rodriguez, E. Vallespín, A. Montesa, D. Lorente Estelles, J.C. Villaguzmán, G. Grau, A. Rodriguez-Vida, K. Ibañez, E. Gonzalez-Billalabeitia, L. Magraner, J. Garde, S. Hernando Polo, J. Arranz Arija, R. Villatoro, B. Pérez Valderrama, P. Lapunzina, E. Castro Marcos, D. Olmos Hidalgo
Journal: Annals of Oncology (2017)
TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas
Authors: S. Dueland, J.W. Valle, K. Bell, O. Faluyi, H. Staiger, T.J. Gjertsen, A-S. Møller, A-K. Aksnes, D. Palmer
Journal: Annals of Oncology (2017)
A human case of swine influenza virus infection in Europe – implications for human health and research
Authors: K Van Reeth, A Nicoll
Journal: Eurosurveillance (2009)

Swine are susceptible to the same influenza A virus subtypes as humans--H1N1, H3N2 and H1N2--and the histories of influenza in pigs and people are closely linked. Many swine influenza viruses are a result of reassortment and their genes are composed of human and avian and/or swine virus genes. Indeed, it is known that both human and avian influenza viruses occasionally transmit to pigs, and that pigs can serve as "mixing vessels" for these viruses, meaning that viruses can exchange genetic material and lead to the production of a new "hybrid" virus. This has led to the thinking that perhaps pandemic viruses could emerge following reassortment in pigs. However, since nobody has observed the start of a pandemic, there remains no direct evidence to make this more than a theory.
Abstract 15563: Inferolateral Early Repolarization Among Non-ischemic Sudden Cardiac Death Victims
Authors: Lauri Holmström, Anette Haukilahti, Jani Tikkanen, Aapo Aro, Tuomas Kenttä, Marja-Leena Kortelainen, Heikki Huikuri, Juhani Junttila
Journal: Circulation (2016)

Introduction: Inferolateral early repolarization (ER) has been associated with an increased risk of sudden cardiac death (SCD) in case-control studies and also in general population. Recent studies...
Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
Authors: Ashwin Rammohan, Mettu S. Reddy, Mohammed Farouk, Joy Vargese, Mohamed Rela
Journal: Hepatology (2017)

Rammohan, Ashwin; Reddy, Mettu S.; Farouk, Mohammed; Vargese, Joy; Rela, Mohamed Author Information
<i>HLA</i> class II alleles of susceptibility and protection in Brazilian and Dutch pemphigus foliaceus
Authors: L. de Sena Nogueira Maehara, F.C. De-Souza-Santana, A.M. Porro, E.V.C. Marcos, S. Ura, I.M. Nolte, H.H. Pas, M.F. Jonkman, J. Tomimori
Journal: British Journal of Dermatology (2017)

Pemphigus foliaceus (PF) is a worldwide chronic autoimmune bullous disease targeting desmoglein 1 (Dsg 1) on epithelial cell surface of skin and mucous membranes, causing lesions in skin but sparing mucosa, since the latter contain compensating desmoglein 3(1) . Several environmental triggers for the autoimmune reaction have been imputed, such as drugs, ultraviolet radiation and mercurium. Human leucocyte antigens class II (HLA-DR4) alleles were linked to the disease in Ashkenazi Jews and other populations(2) . For endemic pemphigus foliaceus in Brazil, named fogo selvagem (FS), HLA-DRB1*04 was shown to have a relative risk >14 for the disease(3) . This article is protected by copyright. All rights reserved.
Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study.
Authors: Antonino Musolino, Maria Michiara, Daniela Boggiani, Angelica Sikokis, Anita Rimanti, Benedetta Pellegrino, Eugenia Martella, Francesco Bozzani, Paolo Sgargi, Michele Panebianco, Giancarlo Bisagni, Fabio Falcini, Carmine Pinto
Journal: Journal of Clinical Oncology (2015)

594 Background: Outcomes for women with pT1aN0M0 breast cancers (BC) may vary by biologic subtype. A higher proportion of HER2-positive BCs diagnosed in the interval between scheduled screening rounds has been proposed to account for the more aggressive behaviour of interval cancers (IC) compared with screen-detected (SD) tumors. No data are available on the prognostic role of HER2-positive status in a general population of pT1aN0M0 breast tumors with known screening status. Methods: All incident pT1aN0M0 BCs (n = 874), systematically collected by the Cancer Registries of Emilia Romagna Region (northern Italy) and diagnosed in women aged 50-69 from 2003 to 2009 were evaluated. Screening status was ascertained by reference to the Emilia Romagna Breast Cancer Screening Program (ERBSP) database. Patients unexposed to screening, with HER2 unknownprimary tumor and/or who received adjuvant chemotherapy or trastuzumab were excluded from analysis. Results: Twelve percent of patients had HER2-positive tumors. Fifty-three percent of the entire study population were SD cancers, while 18% were ICs. Tumors with high histologic grade, high proliferative rate, negative estrogen receptor status, or HER2-positive status were more likely to be diagnosed in the interval between screening. At a median follow-up of 84 months, there were 39 recurrences. The 5-year disease-free survival (DFS) rates were 89% and 95% in patients with HER2-positive and HER2-negative tumors, respectively (P = 0.025). In multivariate analysis, patients with HER2-positive tumors had higher risks of recurrence (hazard ratio [HR], 2.58; 95% CI, 1.38 to 5.3; P= 0.01) than those with HER2-negative tumors. Conclusions: In a general population of pT1aN0M0early BCs with known screening status, HER2-positive tumors account for a substantial proportion of screening failure and have a significant risk of relapse. Final analysis of this study will evaluate if IC detection may identify patients with HER2-positive pT1aN0M0 tumors in whom the rate of recurrence justifies consideration for systemic, anti-HER2, adjuvant therapy.
A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa)
Authors: D. Kilari, E. Guancial, D. Sahasrabudhe, K. Bylow, L. Sievert, K. Schaffer, M. Riese, J. Burfeind, K. Musto, C. Feng, E. Messing, S. Mohile, C. Fung
Journal: Annals of Oncology (2017)